Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in KoreaGlobeNewsWire · 2 days ago
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual MeetingGlobeNewsWire · 5 days ago
Alpha Tau to Participate in October Investor ConferencesGlobeNewsWire · Oct 5, 2026
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And MoreSeeking Alpha · Sep 11, 2026
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM BreakthroughSeeking Alpha · Sep 4, 2026
Alpha Tau to Participate in September Investor ConferencesGlobeNewsWire · Sep 2, 2026Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.14 | -$0.50 | Miss |
| May 18, 2026 | -$0.13 | -$0.26 | Miss |
| Mar 9, 2026 | -$0.13 | -$0.14 | Miss |
| Nov 20, 2025 | -$0.12 | -$0.14 | Miss |
| Aug 11, 2025 | -$0.12 | -$0.13 | Miss |
| May 19, 2025 | -$0.14 | -$0.12 | Beat |